This week, the overall grades of five Medical Devices stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Synergetics USA (NASDAQ:SURG) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Synergetics USA develops and manufactures medical devices and products for the hospital and healthcare communities. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Surprise, SURG also gets F’s. The price of SURG dropped 10.1% since last month, worse than the Nasdaq’s 4.1% decline over the same period. For a full analysis of SURG stock, visit Portfolio Grader.
Alere (NYSE:ALR) earns a F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Alere develops and manufactures patient diagnosis, monitoring, and health management products and services for cardiology, infectious diseases, toxicology, diabetes, oncology, and womens health in the United States and internationally. The stock gets F’s in Earnings Momentum and Equity. Shares of the company have declined 1.6% from a month prior. For more information, get Portfolio Grader’s complete analysis of ALR stock.
Staar Surgical (NASDAQ:STAA) earns a D this week, moving down from last week’s grade of C. Staar Surgical develops, manufactures, and markets high margin visual implants that improve a patient’s quality of vision. The stock also rates an F in Earnings Revisions. The stock price has dropped 13.6% over the past month, worse than the 4.1% decrease the Nasdaq has seen over the same period of time. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. The trailing PE Ratio for the stock is 653.00. To get an in-depth look at STAA, get Portfolio Grader’s complete analysis of STAA stock.
AtriCure (NASDAQ:ATRC) gets weaker ratings this week as last week’s D drops to a F. AtriCure engages in developing, manufacturing, and selling cardiac surgical ablation systems designed to create precise lesions or scars in cardiac tissue in the United States and internationally. The stock also gets an F in Equity. Wall Street appears to agree with the stock downgrade, with share prices dropping 15.3% over the past month. For a full analysis of ATRC stock, visit Portfolio Grader.
This week, NxStage Medical (NASDAQ:NXTM) drops from a D to a F rating. NxStage Medical is medical device company that develops, manufactures, and markets systems for the treatment of end-stage renal disease and acute kidney failure. The stock also gets an F in Equity. The stock price has fallen 15.5% over the past month. To get an in-depth look at NXTM, get Portfolio Grader’s complete analysis of NXTM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.